Efficacy of symptoms of Lower Urinary Tract Dysfunction Research Network Symptom Index-29 questionnaire in assessing alpha-blocker treatment response in patients with benign prostatic hyperplasia: A prospective, multicenter, cohort study
Abstract
OBJECTIVE
To evaluate the efficacy of the symptoms of Lower Urinary Tract Dysfunction Research Network Symptom Index-29 questionnaire (LURN SI-29) in assessing alpha-blocker treatment response in patients with LUTS.
METHODS
This prospective, non-randomised, multicentre trial included males with LUTS who visited urology outpatient clinics between January and April 2023. The most employed LUTS questionnaire is the International Prostate Symptom Score (IPSS), while the LURN SI-29 was also utilised. Prospective monitoring comprised the completion of IPSS and LURN SI-29 forms, uroflowmetry, and residual urine assessment prior to the initiation of alpha-blocker therapy and at the conclusion of the first month of treatment.
RESULTS
The study cohort comprised 135 patients. There was a significant enhancement in the mean IPSS, which decreased from 18.4 to 11.2 (p=0.001). Furthermore, the mean LURN SI-29 score exhibited a significant decline, from 37.02 to 22.4 (p=0.001). The improvement in IPSS and LURN SI-29 scores was 67.1%±54.3% and 64.2%±34.1%, respectively. Additionally, these improvements were found to be correlated (Pearson correlation coefficient=0.79, R2=0.63, p=0.001). The mean Qmax increased from 10.3 ml/s to 11.9 ml/s (p=0.001). No significant difference was identified between alpha-blocker types.
CONCLUSION
A strong correlation was observed between LURN SI-29 and IPSS among patients with LUTS who were initiated on alpha-blocker therapy. LURN-SI-29 may be employed for the…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 135 participants or records.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.